Canaccord Genuity Group reaffirmed their buy rating on shares of Diaceutics (LON:DXRX – Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. Canaccord Genuity Group currently has a GBX 160 ($2.11) price objective on the stock.
Diaceutics Trading Down 0.7 %
Diaceutics stock opened at GBX 133 ($1.76) on Tuesday. The company has a 50 day moving average price of GBX 128.68 and a 200 day moving average price of GBX 118.03. The company has a debt-to-equity ratio of 2.95, a quick ratio of 9.92 and a current ratio of 6.40. Diaceutics has a 52 week low of GBX 82 ($1.08) and a 52 week high of GBX 136 ($1.80). The firm has a market capitalization of £112.33 million, a price-to-earnings ratio of -6,650.00 and a beta of 0.58.
About Diaceutics
Featured Articles
- Five stocks we like better than Diaceutics
- How to Calculate Options Profits
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- 3 REITs to Buy and Hold for the Long Term
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What Do S&P 500 Stocks Tell Investors About the Market?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.